BioStem Technologies Provides Update on the Company's Form 10 Submission and SEC Review Process

Stock Information for BioStem Technologies Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioStem Technologies Inc

BioStem Technologies Completes Enrollment in Clinical Trial Evaluating BioREtain® Amnion Chorion for Treatment of Diabetic Foot Ulcers
Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award Winner
BioStem Technologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
BioStem Announces Notice of Allowance for Three New U.S. Patent Applications
Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist
BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results
BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting
BioStem Technologies to Host First Quarter 2025 Financial Results Conference Call on May 12, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.